All In Biotech

NDA 020803 · Bausch and Lomb

Alrex

Loteprednol Etabonate · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Dec 16, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 9, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

1,209

434 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 7, 2026.

INDICATIONS AND USAGE Loteprednol Etabonate Ophthalmic Suspension, 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ALREX · LOTEPREDNOL ETABONATE 0.2% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain178
  • eye irritation143
  • drug ineffective108
  • off label use85
  • headache79
  • ocular hyperaemia73
  • fatigue62
  • photophobia57
  • eye swelling48
  • vision blurred48
  • lacrimation increased44
  • dry eye43

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20058
20063
20073
200815
200912
201029
201115
201223
201315
201416
201542
201654
201746
201862
201963
202065
202188
202295
2023121
2024159
2025146
2026125

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alrex (Loteprednol Etabonate)

2024 spending

$6.4M

Beneficiaries

8,294

16,908 claims

Per beneficiary

$766

$55.83 per unit

View as table
YearSpending
2020$9,764,845
2021$10,098,001
2022$10,734,692
2023$10,907,860
2024$6,353,196

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.